Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL11515942 | 0.98 | ALDH1A1 (0.70) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| Methoxymethane SCHEMBL27770059 | 0.94 | ALDH1A1 (0.65) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| Acetaldehyde SCHEMBL27922507 | 0.93 | MAPT (0.63) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL5586057 | 0.88 | MAPT (0.57) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL18344445 | 0.88 | MAPT (0.57) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL21359707 | 0.86 | KMT2A (0.73) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL28778523 | 0.85 | MAPT (0.55) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL18183374 | 0.84 | MAPT (0.73) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL77739 | 0.83 | KMT2A (0.73) | ALDH1A1MAPTCYP3A4CYP2C9PKM | |
| SCHEMBL21667263 | 0.80 | MEN1 (0.50) | ALDH1A1MAPTCYP3A4CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421264-B2 | Compounds and methods for the treatment of pathogenic Neisseria | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2025-09-23 | — | — | US | claimed |
| EP-4320094-A1 | NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF | Cosmas Therapeutics Development Inc. (CA) | 2024-02-14 | — | — | EP | claimed |
| WO-2022213195-A1 | NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF | COSMAS THERAPEUTICS DEVELOPMENT INC. (CA) | 2022-10-13 | — | — | WO | claimed |
| US-20220089626-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2022-03-24 | — | — | US | claimed |
| WO-2020051701-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2020-03-19 | — | — | WO | claimed |
| WO-2019169478-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES USING N,N,N-TRIMETHYLCHITOSAN | OVENSA INC. (CA) | 2019-09-12 | — | — | WO | claimed |
| CN-105640890-A | Sparingly soluble active component particle, particle preparation and preparation method thereof | 华东理工大学 | 2016-06-08 | — | — | CN | claimed |
| CN-103565814-B | The pharmaceutical composition that prevention and therapy intracranial pressure increases | 和光学 | 2016-06-08 | — | — | CN | claimed |
| CN-103613527-B | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2016-02-24 | — | — | CN | claimed |
| CN-204676017-U | A kind of phenylethyl barbituric acid crude product centrifugal device | JINGHUA PHARMACEUTICAL GROUP NANTONG CO LTD | 2015-09-30 | — | — | CN | claimed |
| EP-1448528-A2 | PREPARATION OF PHARMACEUTICAL SALTS OF 4((Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL)-1'-((2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL)-4'-METHYL-1,4'BIPIPERIDINE AS CCR5-ANTAGONISTS FOR THE TREATMENT OF AIDS AND RELATED HIV INFECTIONS | SCHERING CORPORATION (US) | 2004-08-25 | — | — | EP | claimed |
| CN-1157365-C | Monoamine uptake inhibitors for the treatment of CNS disorders | �Ʒ� | 2004-07-14 | — | — | CN | claimed |
| CN-1449416-A | Functionalized polymeric media for separation of analytes | MALLINCKRODT INC (US) | 2003-10-15 | — | — | CN | claimed |
| WO-2003066593-A2 | PREPARATION OF PHARMACEUTICAL SALTS OF 4 ( (Z) - (4-BROMOPHENYL) (ETHOXYIMINO) METHYL )-1'-( (2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL) CARBONYL) -4'-METHYL-1,4' BIPIPERIDINE AS CCR5-ANTAGONISTS FOR THE TREATMENT OF AIDS AND RELATED HIV INFECTIONS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030144510-A1 | receptor which are useful for the treatment of AIDS and related HIV infections, including the compound of Formula I. CCR-5 receptors have also been reported to mediate cell transfer in inflammatory diseases such as arthritis, | SCHERING CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030139446-A1 | Preparation of pharmaceutical salts | SCHERING CORPORATION | 2003-07-24 | — | — | US | claimed |
| WO-2003048153-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS HAVING AN INCREASED AMOUNT OF PHARMACEUTICALLY ACTIVE SALTS OF ROTAMERS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| CN-1353719-A | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | claimed |
| CN-1341094-A | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER PROD INC (US) | 2002-03-20 | — | — | CN | claimed |
| EP-0339054-B1 | MIXTURE OF SUBSTANCES FOR STABILYZING METABOLISM | BILAS ANDOR (AT) | 1994-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139446-A1 | Preparation of pharmaceutical salts | PKD1, REN, ADCYAP1R1 | ALDH1A1 1255/4885MAPT 2771/4885CYP3A4 589/4885 |
| US-20220089626-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA | NMBR, MLEC, BPGM | ALDH1A1 2797/4885MAPT 2341/4885CYP3A4 681/4885 |
| US-20030144510-A1 | receptor which are useful for the treatment of AIDS and related HIV infections, including the compound of Formula I. CCR-5 receptors have also been reported to mediate cell transfer in inflammatory diseases such as arthritis, | CCR1, CCR5, CCR6 | ALDH1A1 845/4885MAPT 4014/4885CYP3A4 2970/4885 |
| US-12421264-B2 | Compounds and methods for the treatment of pathogenic Neisseria | NMBR, MLEC, BPGM | ALDH1A1 2797/4885MAPT 2341/4885CYP3A4 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.